THERACLION overview

Regulatory News: This press release must not be published, distributed, or disseminated, directly or indirectly, in the United Kingdom, the United States of America, Australia, Canada, or Japan. THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, today announces the reserved issuance of a convertible bond loan for a maximum amount of €6 million. This financing is carried out...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces today that its latest generation SONOVEIN® ‘SpeedPulse’ feature is being tried on patients. Major R&D breakthroughs in recent months SONOVEIN® achieved a new level of maturity in 2024, with Theraclion maintaining its focus on ongoing R&D and innovation. Key progress has recently been made on the...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy for the treatment of varicose veins, reports on its 2024 activities. Theraclion announced in its press release of January 6, 2025, the continuation of the strategic refocusing on the varicose veins market and confirmed its decision to no longer market its Echopulse machines intended to treat the thyroid in the near...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy for the treatment of varicose veins, reports on its 2024 activities. On-track progress of the pivotal FDA clinical trial Sharp increase in the number of scientific presentations and publications Over 3,000 SONOVEIN ® treatments performed to date Product maturity reached and commercialization accelerated Martin...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, presents its review of the first half of 2023, marked by the achievement of milestones in the deployment of its strategy and the growth of its sales. Roadmap implementation In the first half of 2023, Theraclion appointed its new CEO, Martin Deterre, signed a partnership with Furui and secured the necessary funding for the next two...

Regulatory News: This document may not be distributed, directly or indirectly, in the United States, Canada, Australia or Japan. THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announces today the final signature of the strategic agreement with its long-standing partner Furui, and the completion of an issue of new shares, for a total gross amount of 8.4 million euros, with 1.3 additional million...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announced today the signing of a strategic agreement with its long-term partner Furui, the launch of a financing with various investors for a total amount of up to 15M€, which would allow it to finance the deployment of its strategy over 3 years, and the appointment of its new CEO, Martin Deterre. Accelerated strategy execution...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, presents its 2022 financial results and informs on the company's short-term financing. As of the date of this press release, Theraclion is in position to meet its cash flow needs through July. Negotiations with potential strategic partners are continuing and should be concluded next month. This partnership would include a...